IOX1, the clinical pharmacological inhibitors of ALKBH5, competitively inhibits 2OG binding and suppresses ALKBH5, which demonstrates protective effects against acute kidney injury and sevoflurane-induced neuronal damage in the hippocampus (Li et al., 2016; Chen J. et al., 2023; Meng et al., 2024). The gene discussed is ALKBH5; the disease is acute kidney injury.